Electronic Cigarettes and Nicotine Pouches for Smoking Cessation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05715164|
Recruitment Status : Not yet recruiting
First Posted : February 6, 2023
Last Update Posted : February 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Pakistan is one of the most vulnerable low- and middle-income countries with 29 million adult active tobacco users. Smoking cessation services are lacking as the tobacco control initiatives have largely failed to address the smoking endemic. Over the last five years, Pakistan has witnessed the use of innovative tobacco harm reduction such as e-cigarettes, nicotine pouches, and non-nicotine replacement therapies (non-NRTs). However, their use remains limited.
THR products are imported legally as consumer goods and are taxable. The lack of sufficient data for THR and its application is a challenge in gauging their effectiveness in assisting smokers to quit combustible smoking. Evidence-based studies on e-cigarettes and other nicotine products are required to gauge the effectiveness of e-cigarettes and nicotine pouches as smoking cessation aids.
Keeping in view the study objectives, a sample size of 600 participants will be sufficient to assess the effectiveness of e-cigarettes and nicotine pouches for smoking cessation in Pakistan. Of these, 200 participants each will receive e-cigarettes and nicotine pouches along with basic care counseling, while the remaining 200 participants will only receive basic care counseling for 48 weeks. The association of participants' characteristics with smoking and health status will be based on bivariate and multivariate analysis. The simple t-test and variance analysis will assess the differences in intervention indicators between the control and treatment groups. For the inferential analysis, the average treatment impact of the treatments will find using quasi-experimental techniques such as difference in difference (DID) or Propensity Score Matching (PMS).
This study will be evaluated participants at baseline, after their self-decided "quit date,". The follow-up will be a survey every 12 weeks. Results may inform the public, decision-makers, and researchers about the use of e-cigarettes and nicotine pouches helping smokers to quit smoking or switch to less harmful alternatives in the short- and medium-term periods.
|Condition or disease||Intervention/treatment||Phase|
|Role of Tobacco Harm Reduction in Smoking Cessation Efficiency and Efficacy of E-cigarettes and Nicotine Pouches Adverse Effect of E-cigarettes and Nicotine Pouches||Device: E-cigarettes device plus liquid Drug: Nicotine Pouches Other: Basic care counseling about smoking cessation||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||600 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The baseline survey will help to evaluate the smoking status, smoking behavior, socio-demographic characteristics, health status, etc. The three-arm study design would randomize 600 participants into three groups. Of the 600 participants, 200 each will receive e-cigarettes, nicotine pouches, and basic care counseling respectively. Four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches or e-cigarettes. All participants will complete a follow-up survey at 60 weeks. The provision of e-cigarettes and nicotine pouches will be stopped after the first 48 weeks. The remaining 12 weeks will be without the provision of any intervention and the participants must buy these items on their own.|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Electronic Cigarettes and Nicotine Pouches for Smoking Cessation in Pakistan: A Randomized Controlled Trial|
|Estimated Study Start Date :||December 2023|
|Estimated Primary Completion Date :||April 2024|
|Estimated Study Completion Date :||April 2025|
Experimental: E-cigarettes device plus liquid
The 200 participants will receive e-cigarettes along with basic care counseling for 48 weeks.
Device: E-cigarettes device plus liquid
The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
Experimental: Nicotine Pouches
The 200 participants will receive nicotine pouches along with basic care counseling for 48 weeks.
Drug: Nicotine Pouches
The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
Active Comparator: Basic care counseling about smoking cessation
The 200 participants will receive basic care counseling for 48 weeks.
Other: Basic care counseling about smoking cessation
The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
- Number of participants reported adverse events of e-cigarettes or nicotine pouches [ Time Frame: 60 Weeks ]The primary outcome will be a long-term change in health status. The best proxy indication for demonstrating a change in tobacco smoking, which is adequate to result in a clinically relevant long-term health benefit, is unknown. In the absence of accurate health indicators, we will use the change in smoking rate from baseline and smoking cessation as primary outcomes.
- Change in the number of combustible cigarettes per day [ Time Frame: 60 Weeks ]This study will evaluate the impact of e-cigarettes and nicotine pouches on cigarettes per day (CPD) and smoking cessation (7 Day Point Abstinence) at weeks 24 and 48.
- Point-prevalence abstinence [ Time Frame: 60 Weeks ]Self-reported point-prevalence abstinence in the previous week with biochemical validation will be used exhaled carbon monoxide less than 10 parts per million (PPM).
- 7-day point-prevalence abstinence and harm reduction [ Time Frame: 60 Weeks ]Secondary outcomes will include 7-day point-prevalence abstinence (at all subsequent check-ups) (biochemically validated at weeks 12, 24, 36, 48, and 60). As a secondary goal, this study will analyze the harm-reduction effect of e-cigarettes and nicotine pouches, as well as the analysis of adverse events.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Participants who are at least eighteen years old.
- More than 10 combustible cigarettes smoke a day at the time of study enrollment.
- Smoked cigarettes for at least a year.
- Participants are willing to stop combustible smoking.
- Participants who can sign a written consent form.
- There can only be one applicant per household.
- Own a phone that supports text massaging.
- Women who are pregnant.
- Childbearing mothers.
- Currently using other nicotine- and non-nicotine-based cessation therapies.
- Expectant ladies who intend to become pregnant during the trial's participation term.
- Experienced chest pain, or another cardiovascular event or procedure (e.g., heart attack, stroke, insertion of stent, bypass surgery).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05715164
|Contact: Abdul Hameed, PhDfirstname.lastname@example.org|
|Contact: Daud Malik, MAemail@example.com|
|Rawalpindi and Islamabad Centre|
|Rawalpindi, Punjab, Pakistan, 46000|
|Contact: Sarnawaz Salamat, Msc firstname.lastname@example.org|
|Principal Investigator: Juniad Khan, Msc|
|Sub-Investigator: Sarnawaz Salamat, Msc|
|Responsible Party:||Dr Abdul Hameed, Research Lead, Alternative Research Initiative|
|Other Study ID Numbers:||
|First Posted:||February 6, 2023 Key Record Dates|
|Last Update Posted:||February 6, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Nicotine Replacement Therapy
Tobacco Harm Reduction
Peripheral Nervous System Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action